Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
PHASE-I TRIAL OF HIGH-DOSE FOSFESTROL IN HORMONE-REFRACTORY ADENOCARCINOMA OF THE PROSTATE
Autore:
DROZ JP; DESMEDT E; KATTAN J; KEUPPENS F; KHOURY S; MAHLER C; DENIS L;
Indirizzi:
INST GUSTAVE ROUSSY,DEPT MED,39 RUE C DESMOULINS F-94800 VILLEJUIF FRANCE HOP PITIE,DEPT UROL PARIS FRANCE AZ MIDDELHEIM,DEPT UROL ANTWERP BELGIUM AZ MIDDELHEIM,DEPT MED ANTWERP BELGIUM VUB,AZ,DEPT UROL BRUSSELS BELGIUM
Titolo Testata:
The Prostate
fascicolo: 2, volume: 24, anno: 1994,
pagine: 62 - 66
SICI:
0270-4137(1994)24:2<62:PTOHFI>2.0.ZU;2-3
Fonte:
ISI
Lingua:
ENG
Soggetto:
CARCINOMA; CANCER; DIETHYLSTILBESTROL; DISEASE;
Keywords:
PROSTATE CANCER; HORMONE RESISTANCE; HIGH-DOSE FOSFESTROL;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
20
Recensione:
Indirizzi per estratti:
Citazione:
J.P. Droz et al., "PHASE-I TRIAL OF HIGH-DOSE FOSFESTROL IN HORMONE-REFRACTORY ADENOCARCINOMA OF THE PROSTATE", The Prostate, 24(2), 1994, pp. 62-66

Abstract

Androgen deprivation displays the mean therapy of advanced stage prostatic cancer. The development of hormone-resistant disease leads to a fatal tumor progression. High-dose fosfestrol (diethylstilbestrol disphosphate) has been suggested to circumvent hormone resistance and to induce a direct cytotoxic effect. Twenty-one patients with hormone-refractory prostate cancer were enrolled in a phase I trial of continuous infusion of high, daily escalating dose of fosfestrol. Fosfestrol was given in a 3.5 hr infusion in 0.9% normal saline at a starting dose of1.5 g/d. The dose was increased daily in the same patient according to the following schedule: 1.5, 1.8, 2.4, 3.0, 3.6, 3.9, 4.5, 5.1 and 5.7 g/d. The duration of the infusion was prolonged to 7 or 10.5 hr, ifa major side effect occurred. There was neither hematological nor cardiovascular toxicity. The main dose-limiting toxicities were nausea/vomiting in 17 patients, edema in 2 patients, and more than 5% weight gain in 3 patients. The planned maximal dose was reached in 10 patients during a 3.5 hr infusion, and in 3 additional patients, after infusionprolongation. Seven patients experienced a subjective improvement. Prostatic acid phosphatase and prostatic specific antigen decreased in 4out of 11 and in 7 out of 12 patients, respectively. The suggested dose to phase II trial is 4 g/d in 3.5 hr infusion for a duration of up to 10 days. (C) 1994 Wiley-Liss, Inc.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 29/09/20 alle ore 07:21:29